covid-19 |
126 |
chinese |
97 |
humans |
94 |
sars-cov-2 |
72 |
adult |
70 |
male |
68 |
animals |
63 |
epidemiology |
63 |
diabetes |
61 |
female |
57 |
children |
55 |
apoptosis |
51 |
mortality |
48 |
hong kong |
47 |
obesity |
47 |
middle aged |
46 |
aged |
45 |
cardiovascular disease |
45 |
interprofessional education |
44 |
medical sciences |
43 |
stroke |
43 |
diabetes mellitus |
42 |
inflammation |
42 |
atrial fibrillation |
41 |
cancer |
40 |
covid-19 vaccine |
39 |
mice |
38 |
type 2 diabetes mellitus |
38 |
hypertension |
37 |
osteoporosis |
36 |
oxidative stress |
35 |
quality of life |
35 |
colorectal cancer |
34 |
heart failure |
34 |
adiponectin |
33 |
primary care |
31 |
rats |
31 |
cohort studies |
30 |
nitric oxide |
30 |
bnt162b2 |
29 |
coronavac |
29 |
health-related quality of life |
29 |
myocardial infarction |
29 |
vaccine safety |
29 |
partnership model |
28 |
public health |
28 |
risk factors |
28 |
social interaction anxiety |
28 |
amino acid sequence |
27 |
cells, cultured |
27 |
china |
27 |
covid-19 vaccines |
27 |
atherosclerosis |
26 |
insulin resistance |
26 |
reactive oxygen species |
26 |
breast cancer |
25 |
cell line |
25 |
cytokines |
25 |
molecular sequence data |
25 |
cardiovascular diseases |
24 |
safety |
24 |
validation |
23 |
adolescents |
22 |
blood pressure |
22 |
dose-response relationship, drug |
22 |
meta-analysis |
22 |
biomarker |
21 |
dementia |
21 |
reactive oxygen species - metabolism |
21 |
reliability |
21 |
school closure |
21 |
systematic review |
21 |
validity |
21 |
blotting, western |
20 |
ischemic stroke |
20 |
vitamin d |
20 |
adolescent |
19 |
cholesterol |
19 |
depression |
19 |
lung cancer |
19 |
metformin |
19 |
responsiveness |
19 |
sars |
19 |
secondary prevention |
19 |
type 2 diabetes |
19 |
alzheimer's disease |
18 |
asthma |
18 |
biology |
18 |
cohort study |
18 |
inactivated vaccine |
18 |
insulin |
18 |
metabolic syndrome |
18 |
pharmacoepidemiology |
18 |
pre-diabetes |
18 |
pregnancy |
18 |
reverse transcriptase polymerase chain reaction |
18 |
rna, messenger - metabolism |
18 |
screen time |
18 |
self-controlled case series |
18 |
signal transduction - drug effects |
18 |
tuberculosis |
18 |
adipose tissue |
17 |
angiogenesis |
17 |
asian continental ancestry group |
17 |
aspirin |
17 |
endothelium |
17 |
vaccination |
17 |
adult learning principles |
16 |
aging |
16 |
bone mineral density |
16 |
bronchiectasis |
16 |
cell line, tumor |
16 |
child psychosocial problems |
16 |
collaborative practice |
16 |
coronavirus |
16 |
cyclooxygenase |
16 |
evaluation |
16 |
gene expression |
16 |
genotype |
16 |
healthcare workers |
16 |
home confinement |
16 |
hong kong - epidemiology |
16 |
hospital policies |
16 |
macrophages |
16 |
perceived stress |
16 |
pharmacy and pharmacology environmental studies |
16 |
physical activity |
16 |
polymorphism, single nucleotide |
16 |
psychological wellbeing |
16 |
risk stratification |
16 |
time factors |
16 |
toxicology and environmental safety |
16 |
traditional chinese medicine |
16 |
warfarin |
16 |
adverse events |
15 |
amino acid substitution |
15 |
ampk |
15 |
apoptosis - drug effects |
15 |
base sequence |
15 |
biomarkers |
15 |
body mass index |
15 |
cost-effectiveness |
15 |
endothelial cells |
15 |
endothelial function |
15 |
immunohistochemistry |
15 |
infants |
15 |
innate immunity |
15 |
microvascular complications |
15 |
odds ratio |
15 |
prevalence |
15 |
rats, sprague-dawley |
15 |
sf-12 |
15 |
signal transduction |
15 |
tissue distribution |
15 |
vaccine effectiveness |
15 |
aged, 80 and over |
14 |
algorithms |
14 |
autophagy |
14 |
bacteria |
14 |
calcium |
14 |
cell proliferation - drug effects |
14 |
colon cancer |
14 |
complications |
14 |
coronavirus infection |
14 |
health outcomes |
14 |
immunoglobulin |
14 |
kinetics |
14 |
metabolism |
14 |
mice, inbred c57bl |
14 |
nf-κb |
14 |
polymerase chain reaction |
14 |
protein structure, tertiary |
14 |
rheumatoid arthritis |
14 |
sex difference |
14 |
antibiotics |
13 |
bone density |
13 |
cardiovascular complications |
13 |
chemicals and cas registry numbers |
13 |
chronic disease |
13 |
cigarette smoking |
13 |
cost |
13 |
fracture |
13 |
general diabetes |
13 |
gut microbiota |
13 |
hepatocellular carcinoma |
13 |
low-income families |
13 |
lymphocyte subsets |
13 |
major adverse cardiovascular events |
13 |
mendelian randomization |
13 |
menopause |
13 |
patient-reported outcomes |
13 |
prognosis |
13 |
up-regulation |
13 |
adipokine |
12 |
allergy |
12 |
animal experiment |
12 |
antioxidants |
12 |
asia |
12 |
blotting, northern |
12 |
child health |
12 |
chinese medicine |
12 |
convalescence |
12 |
electrophoresis, gel, two-dimensional |
12 |
endothelial dysfunction |
12 |
enzyme inhibitors - pharmacology |
12 |
enzyme-linked immunosorbent assay |
12 |
false positive |
12 |
gene frequency |
12 |
hypoxia |
12 |
kawasaki disease |
12 |
mental health |
12 |
models, biological |
12 |
paediatrics |
12 |
plasma |
12 |
prospective studies |
12 |
proteomics |
12 |
psychometrics |
12 |
pulmonary delivery |
12 |
quality of care |
12 |
sars-cov-2 rbd igg |
12 |
serology |
12 |
stress |
12 |
survival |
12 |
t cell response |
12 |
analgesia |
11 |
asian continental ancestry group - genetics |
11 |
bmd |
11 |
child maltreatment |
11 |
colonoscopy |
11 |
confirmatory factor analysis |
11 |
disease models, animal |
11 |
disease progression |
11 |
double-blind method |
11 |
endocrinology |
11 |
hrqol |
11 |
hypersensitivity |
11 |
lipid |
11 |
lipids |
11 |
older adults |
11 |
omicron |
11 |
pharmacy |
11 |
pneumonia |
11 |
preventive medicine |
11 |
prostaglandin e2 |
11 |
respiratory diseases |
11 |
rna interference |
11 |
sglt2 inhibitor |
11 |
statistics & research methods |
11 |
thyroid function tests |
11 |
thyroid gland |
11 |
thyroiditis |
11 |
time in therapeutic range |
11 |
5-fluorouracil |
10 |
adipocytes - metabolism |
10 |
adolescence |
10 |
all-cause pneumonia |
10 |
antioxidants - pharmacology |
10 |
asparaginase |
10 |
autoimmune disorders |
10 |
beta-amyloid |
10 |
bidirectional relationship |
10 |
binding sites |
10 |
bmi |
10 |
bone density - genetics |
10 |
case-control studies |
10 |
catalase |
10 |
causality |
10 |
cigarette smoke |
10 |
contraction |
10 |
cytokine |
10 |
delirium |
10 |
endothelium-derived contracting factor |
10 |
enos |
10 |
enzyme activation - drug effects |
10 |
gastrointestinal haemorrhage |
10 |
gene expression regulation |
10 |
health equity |
10 |
health literacy |
10 |
herbal medicine |
10 |
herd immunity |
10 |
human leukocyte antigens |
10 |
incident cvd |
10 |
interleukin-6 |
10 |
interrupted time series analysis |
10 |
linkage disequilibrium |
10 |
lipocalin-2 |
10 |
liver injury |
10 |
long covid |
10 |
mass spectrometry |
10 |
obstructive sleep apnea |
10 |
osteoarthritis |
10 |
oxidation-reduction |
10 |
oxidative stress - drug effects |
10 |
parental stress |
10 |
pasc |
10 |
pharmacovigilance |
10 |
phospholipids |
10 |
phosphorylation - drug effects |
10 |
pneumococcal conjugate vaccines |
10 |
population-based electronic health records |
10 |
post-acute sequelae of sars-cov-2 |
10 |
post-covid cvd |
10 |
prescribing |
10 |
prevention |
10 |
primary health care |
10 |
proliferation |
10 |
proteomics - methods |
10 |
randomized controlled trial |
10 |
risk assessment |
10 |
risk factor |
10 |
saponin |
10 |
sequence alignment |
10 |
sirt1 |
10 |
statins |
10 |
telomere |
10 |
treatment |
10 |
treatment outcome |
10 |
2-de |
9 |
abdominal pain |
9 |
advanced glycation end-products |
9 |
adverse events of special interest (aesi) |
9 |
age-stratified |
9 |
anchor |
9 |
animal cell |
9 |
antidepressants |
9 |
antimicrobials |
9 |
association |
9 |
biological markers - blood |
9 |
body weight |
9 |
bone loss |
9 |
bradykinin |
9 |
cell membrane - metabolism |
9 |
chronic kidney disease |
9 |
cloning, molecular |
9 |
dna-binding proteins - genetics - metabolism |
9 |
down syndrome |
9 |
drug repurposing |
9 |
drug utilization |
9 |
effectiveness |
9 |
electronic health record |
9 |
extraction |
9 |
fact-c |
9 |
follow-up studies |
9 |
genetics |
9 |
glycosylation |
9 |
green tea |
9 |
health sciences |
9 |
heart |
9 |
hyperglycemia |
9 |
igt |
9 |
in situ hybridization |
9 |
incidence |
9 |
infection |
9 |
lipid metabolism |
9 |
lipoproteins |
9 |
liver |
9 |
liver - metabolism |
9 |
medicine |
9 |
mice, knockout |
9 |
mitochondria |
9 |
molnupiravir |
9 |
mutation |
9 |
nanoparticles |
9 |
nirmatrelvir-ritonavir |
9 |
nomogram |
9 |
nursing |
9 |
organic acid |
9 |
parkinson's disease |
9 |
patient-centered care |
9 |
pediatrics |
9 |
polymorphism, genetic |
9 |
protein binding |
9 |
proteins - genetics |
9 |
regression analysis |
9 |
relaxation |
9 |
rna, messenger - analysis |
9 |
sensitivity |
9 |
serotonin |
9 |
serum 25-hydroxyvitamin d |
9 |
smoking |
9 |
spermatogenesis - physiology |
9 |
superoxide dismutase |
9 |
travel history |
9 |
undergraduate students |
9 |
vaccine |
9 |
vascular smooth muscle |
9 |
viral disease |
9 |
waning vaccine effectiveness |
9 |
a-fabp |
8 |
adipocyte |
8 |
adipokines |
8 |
adiponectin receptor |
8 |
adolescent idiopathic scoliosis |
8 |
adverse events of special interest |
8 |
all-cause mortality |
8 |
anoxia - metabolism |
8 |
anti-inflammatory agents - pharmacology |
8 |
antimicrobial resistance |
8 |
antineoplastic activity |
8 |
antiresorptives |
8 |
anxiety disorder |
8 |
aorta |
8 |
apoptosis - drug effects - physiology |
8 |
appswe/ps1de9 |
8 |
aquaporin 9 |
8 |
assessment |
8 |
aβ |
8 |
bacteremia |
8 |
cdars |
8 |
child |
8 |
clinical pharmacology |
8 |
cognitive impairments |
8 |
comorbidity |
8 |
coronary artery disease |
8 |
dabigatran |
8 |
dialysis |
8 |
diarrhoea |
8 |
dimerization |
8 |
direct medical cost |
8 |
drug regulatory |
8 |
economic burden |
8 |
ehr |
8 |
endothelium-dependent contractions |
8 |
endothelium-derived contracting factors |
8 |
epithelial cells |
8 |
eq-5d-5l |
8 |
escherichia coli |
8 |
family doctor |
8 |
family hardship |
8 |
fib-4 |
8 |
free radicals |
8 |
gastroenterology |
8 |
genetic predisposition to disease |
8 |
glycolipids |
8 |
health disparity |
8 |
heart disease |
8 |
hela cells |
8 |
hepatocytes - metabolism |
8 |
herbal medicines |
8 |
high-fat diet |
8 |
histamine |
8 |
hospitalisation |
8 |
hydrogen peroxide |
8 |
hypercholesterolemia |
8 |
hypertriglyceridemia |
8 |
immunosuppression |
8 |
influenza |
8 |
jak2/stat3 |
8 |
latent class analysis |
8 |
management programme |
8 |
meningitis |
8 |
metabolomic |
8 |
metalloporphyrins - pharmacology |
8 |
mrna vaccine |
8 |
multimorbidity |
8 |
mutagenesis, site-directed |
8 |
myocardial ischemia injury |
8 |
myocarditis |
8 |
neonates |
8 |
nested case-control study |
8 |
nfs |
8 |
nitric oxide - metabolism |
8 |
orphan drug policy |
8 |
p53 |
8 |
paediatric gastroenterology |
8 |
patch-clamp techniques |
8 |
pediatric population |
8 |
pedigree |
8 |
pericarditis |
8 |
pi3k/akt |
8 |
polysaccharide |
8 |
preschooler |
8 |
proto-oncogene proteins c-akt - metabolism |
8 |
psychometric properties |
8 |
questionnaire |
8 |
rare diseases |
8 |
self-harm |
8 |
service utilization |
8 |
sleep duration |
8 |
spa |
8 |
sphingolipids |
8 |
testis - cytology - physiology |
8 |
thiazolidinediones - therapeutic use |
8 |
thyroidectomy |
8 |
transcription, genetic |
8 |
transfection |
8 |
treatment access |
8 |
trs 2°p |
8 |
two-dimensional gel electrophoresis |
8 |
vasoconstriction - drug effects |
8 |
vasodilation - drug effects - physiology |
8 |
wound healing |
8 |
3t3 cells |
7 |
3t3-l1 cells |
7 |
acetic acid |
7 |
acetylcholine |
7 |
acetylcholine - pharmacology |
7 |
acrosome - physiology |
7 |
adenocarcinoma |
7 |
adipogenesis |
7 |
adolescent development |
7 |
adrenergic beta-antagonists - pharmacology |
7 |
adults |
7 |
adverse drug reactions |
7 |
airway epithelial cells |
7 |
alcoholism |
7 |
alzheimer disease |
7 |
angiotensinconverting enzyme inhibitors |
7 |
antimicrobial stewardship |
7 |
asians |
7 |
bariatric surgery |
7 |
bile acids |
7 |
binding, competitive |
7 |
bioactive compounds |
7 |
blood glucose - metabolism |
7 |
bone metabolism |
7 |
c-reactive protein |
7 |
cancer incidence |
7 |
carbapenemase-producing enterobacteriaceae |
7 |
cardiovascular disease risk |
7 |
cardiovascular diseases - epidemiology |
7 |
carriage |
7 |
catalase - metabolism |
7 |
cattle |
7 |
cell fractionation |
7 |
cell proliferation |
7 |
cer1 |
7 |
child behaviour |
7 |
chronic obstructive pulmonary disease |
7 |
colorectal neoplasm |
7 |
copd |
7 |
coriolus versicolor |
7 |
cost-of-illness |
7 |
covid-19 pandemic |
7 |
cross-sectional studies |
7 |
cyclooxygenase-2 |
7 |
cytotoxicity |
7 |
dexamethasone - pharmacology |
7 |
diabetic cardiomyopathy |
7 |
dialysis patients |
7 |
differentiation |
7 |
dpp4 inhibitor |
7 |
drug discovery |
7 |
drug modulation |
7 |
early childhood exposure |
7 |
early detection |
7 |
early onset scoliosis |
7 |
early onset scoliosis-24 questionnaire |
7 |
early-life activities |
7 |
elderly |
7 |
elderly care |
7 |
electronic health records |
7 |
endothelial nitric oxide synthase |
7 |
endothelin-1 |
7 |
endothelium, vascular - drug effects - enzymology - physiology |
7 |
endothelium, vascular - drug effects - metabolism - physiology |
7 |
endothelium, vascular - drug effects - metabolism - physiopathology |
7 |
endothelium-derived hyperpolarizing factor |
7 |
eosq-24 |
7 |
eq-5d |
7 |
family financial pressure |
7 |
family well-being |
7 |
fatty acid-binding proteins - blood |
7 |
forced expiratory volume - physiology |
7 |
gender |
7 |
gene expression - drug effects |
7 |
genetic correlation |
7 |
genetic vectors |
7 |
gluconeogenesis |
7 |
glycated haemoglobin |
7 |
glycolysis |
7 |
guinea pigs |
7 |
haplotypes |
7 |
health care service provider |
7 |
health economic analysis |
7 |
health preference |
7 |
health utility |
7 |
heat-shock proteins - metabolism |
7 |
hemoglobin a1c |
7 |
homeostasis |
7 |
hong kong chinese population |
7 |
ht-29 cells |
7 |
hyperglycaemia |
7 |
hypoglycemic agents - therapeutic use |
7 |
in situ hybridization, fluorescence |
7 |
indirect effect |
7 |
inducible nitric oxide synthase |
7 |
information sharing |
7 |
inhalation |
7 |
intermittent hypoxia |
7 |
intimate partner abuse |
7 |
jnk |
7 |
kidney |
7 |
left ventricular hypertrophy |
7 |
leguminosae |
7 |
lifestyle |
7 |
lipocalin |
7 |
lipopolysaccharide |
7 |
liver cancer |
7 |
lumbar disc degeneration |
7 |
mediation |
7 |
medicine, chinese traditional |
7 |
mental disorders |
7 |
mice, inbred strains |
7 |
mobile apps |
7 |
morphine consumption |
7 |
multiple reaction monitoring |
7 |
nf-kappa b - metabolism |
7 |
nfκb |
7 |
patient enablement |
7 |
patient-reported outcome |
7 |
peritoneal dialysis |
7 |
pharmacology |
7 |
phosphorylation |
7 |
phylogeny |
7 |
placebo |
7 |
pleiotropy |
7 |
polygenic score |
7 |
polyphenols |
7 |
population aging |
7 |
population-based study |
7 |
ppar gamma - agonists - metabolism |
7 |
prediabetes |
7 |
prediabetic state |
7 |
preventive measures |
7 |
proanthocyanidins |
7 |
promoter regions, genetic |
7 |
promoter regions, genetic - genetics |
7 |
prostacyclin |
7 |
prostaglandin |
7 |
protein kinase c - metabolism |
7 |
proteins - genetics - metabolism |
7 |
proteome |
7 |
pseudomonas aeruginosa |
7 |
psychosocial development |
7 |
quality in health care |
7 |
rat |
7 |
rct |
7 |
recombinant fusion proteins - metabolism |
7 |
recombinant proteins - metabolism |
7 |
recurrence |
7 |
renal replacement therapy |
7 |
resistance |
7 |
saliva |
7 |
school closures |
7 |
school-aged children |
7 |
sequence analysis, dna |
7 |
sf-6d |
7 |
sleep |
7 |
small interfering rna |
7 |
soluble guanylyl cyclase |
7 |
spermatozoa - cytology - metabolism |
7 |
spondyloarthritis |
7 |
spray drying |
7 |
substrate specificity |
7 |
tandem mass spectrometry |
7 |
therapeutics |
7 |
thiazolidinediones |
7 |
thyroid |
7 |
tumor‐shrinking decoction |
7 |
ultra‐pressure liquid chromatography coupled tandem mass spectrometry |
7 |
vasoconstriction |
7 |
vasodilatation |
7 |
vasodilation |
7 |
vasodilation - drug effects |
7 |
vasodilator agents - pharmacology |
7 |
visceral fat |
7 |
visit‐to‐visit variability |
7 |
vital capacity |
7 |
waist circumference |
7 |
warburg effect |
7 |
zinc fingers |
7 |
acute liver injury |
6 |
acyl coenzyme a - metabolism |
6 |
adaptor protein |
6 |
adaptor proteins, signal transducing - genetics - metabolism |
6 |
adiponectin - genetics |
6 |
adiponectin - metabolism |
6 |
adipose tissue - chemistry |
6 |
adiposity - physiology |
6 |
administration, inhalation |
6 |
age |
6 |
age factors |
6 |
allele |
6 |
anaphylaxis |
6 |
angiotensin ii |
6 |
angiotensin receptor blockers |
6 |
angiotensin-converting enzyme inhibitors |
6 |
anti-coagulant |
6 |
anti-inflammation |
6 |
antibody |
6 |
antioxidant |
6 |
anxiety |
6 |
appl1 |
6 |
arginine methylation |
6 |
automated |
6 |
biogenesis |
6 |
bioinformatics |
6 |
biological markers - analysis |
6 |
biotin |
6 |
bleeding |
6 |
blood glucose - analysis |
6 |
blood–brain barrier |
6 |
bone mineral testing |
6 |
bone turnover markers |
6 |
bronchial epithelial cells |
6 |
bronchiectasis - metabolism |
6 |
burden of disease |
6 |
c-reactive protein - analysis |
6 |
camp |
6 |
cancer metabolism |
6 |
cardiovascular event |
6 |
cardiovascular mortality |
6 |
carotid artery |
6 |
carotid intima-media thickness |
6 |
cell density |
6 |
challenge |
6 |
chemical constituent |
6 |
child behavior |
6 |
child, preschool |
6 |
cilia |
6 |
ciliary central microtubular orientation |
6 |
collagen |
6 |
controlled study |
6 |
coronary heart disease |
6 |
cost-effectiveness analysis |
6 |
covid-19 incidence |
6 |
cox regression |
6 |
cvd |
6 |
cyclic amp - metabolism |
6 |
cyp2c9 |
6 |
cytokines - genetics |
6 |
cytotoxic activity |
6 |
data repository |
6 |
depolarization |
6 |
diabetes mellitus, type 2 - blood - drug therapy |
6 |
dipeptidyl peptidase-4 inhibitors |
6 |
disease and disorders of/related to bone |
6 |
dna, complementary - genetics |
6 |
doac |
6 |
drug |
6 |
drug delivery |
6 |
drug safety |
6 |
economic evaluation |
6 |
efficacy |
6 |
electrophysiology |
6 |
end-stage renal disease |
6 |
endothelial progenitor cells |
6 |
endothelial senescence |
6 |
endothelium, vascular - metabolism |
6 |
endothelium, vascular - physiology |
6 |
energy metabolism |
6 |
ep4 |
6 |
epidemiological studies |
6 |
erxian decoction |
6 |
erythrocytes - enzymology |
6 |
escherichia coli - genetics |
6 |
esophageal cancer |
6 |
estrogen receptor |
6 |
family breakfast |
6 |
family dinner |
6 |
family functioning |
6 |
family meal |
6 |
fatty liver |
6 |
fracture prevention |
6 |
fractures, bone - genetics |
6 |
ganoderma lucidum |
6 |
gastrointestinal bleeding |
6 |
gastrointestinal tumours |
6 |
gene |
6 |
gene expression profiling - methods |
6 |
general population studies |
6 |
genetic association |
6 |
genetic disease |
6 |
genistein |
6 |
genome-wide association study |
6 |
genome-wide haplotype association mapping (ham) |
6 |
genomics |
6 |
gleditsia sinensis |
6 |
glucagon-like peptide-1 receptor agonists |
6 |
glucocorticoid receptor |
6 |
glucocorticoids |
6 |
glucose intolerance - blood - genetics |
6 |
glutathione peroxidase |
6 |
glyburide - therapeutic use |
6 |
hdl‐c |
6 |
healthcare resource |
6 |
heme oxygenase-1 |
6 |
herb-drug interaction |
6 |
hospital |
6 |
human |
6 |
hydrogen-ion concentration |
6 |
hypertension - epidemiology |
6 |
hypertriglyceridemia - epidemiology |
6 |
impaired glucose tolerance |
6 |
income instability |
6 |
infant, newborn |
6 |
inflammatory bowel disease |
6 |
influenza virus |
6 |
information technology |
6 |
intellectual disability |
6 |
intensive care unit |
6 |
interleukin-6 - biosynthesis |
6 |
intervention |
6 |
intestinal mucositis |
6 |
intra-abdominal fat |
6 |
intracranial hemorrhage |
6 |
intubation |
6 |
ischaemic stroke |
6 |
isoproterenol |
6 |
japan |
6 |
jnk/c-jun signalling |
6 |
job loss |
6 |
ldl‐c |
6 |
likelihood functions |
6 |
lipids variability |
6 |
lkb1 |
6 |
low income |
6 |
measurement invariance |
6 |
membrane proteins - biosynthesis |
6 |
messenger rna |
6 |
meta-data |
6 |
metabolic syndrome x - blood - epidemiology - etiology |
6 |
metabolomics |
6 |
mice, obese |
6 |
microarray |
6 |
mineral metabolism |
6 |
mmp-9 |
6 |
mode of administration |
6 |
multidisciplinary |
6 |
muscle contraction - drug effects |
6 |
muscle relaxation - drug effects |
6 |
muscle, smooth, vascular - drug effects - metabolism |
6 |
musculoskeletal disorders |
6 |
nasopharyngeal |
6 |
neurogen |
6 |
neuroleptic agent |
6 |
neurological and mental health global epidemiology network |
6 |
nocturnal home haemodialysis |
6 |
non-alcoholic steatohepatitis |
6 |
non-communicable disease |
6 |
non-st elevated myocardial infarction |
6 |
non-steroidal anti-inflammatory drugs |
6 |
norepinephrine - pharmacology |
6 |
nsaids |
6 |
obesity - epidemiology |
6 |
obesity - genetics |
6 |
organ culture techniques |
6 |
osteoblasts - metabolism |
6 |
osteoporosis - genetics - metabolism |
6 |
p-pkb |
6 |
panax notoginseng |
6 |
parenting |
6 |
personalized medicine |
6 |
ph domain and leucine zipper containing 1 (appl1) |
6 |
pharmacokinetics |
6 |
phosphotyrosine interaction |
6 |
photodynamic therapy |
6 |
phytotherapy |
6 |
pkm2 |
6 |
pneumonia admission |
6 |
point-of-care testing |
6 |
polysaccharides |
6 |
pomegranate peel ellagitannins |
6 |
predictors |
6 |
prmt6 |
6 |
protein kinase c |
6 |
proteins - metabolism |
6 |
proto-oncogene proteins - genetics - metabolism |
6 |
psychological symptoms |
6 |
pulmonary hypertension |
6 |
questionnaires |
6 |
radioactive iodine |
6 |
radioimmunoassay |
6 |
rage |
6 |
rats, inbred shr |
6 |
rats, inbred wky |
6 |
rats, wistar |
6 |
receptors, immunologic - blood - drug effects |
6 |
reference values |
6 |
renin |
6 |
respiratory syncytial virus |
6 |
respiratory tract infections |
6 |
retrospective cohort |
6 |
retrospective studies |
6 |
rhinitis |
6 |
rickets |
6 |
risk algorithm |
6 |
risk prediction |
6 |
rna, messenger - biosynthesis |
6 |
rosiglitazone |
6 |
salvia miltiorrhiza |
6 |
saponins - pharmacology |
6 |
sensitivity and specificity |
6 |
sequence homology, amino acid |
6 |
single-nucleotide polymorphism |
6 |
sleep apnea, obstructive - metabolism |
6 |
smoking cessation |
6 |
snoring |
6 |
sodium-glucose co-transporter |
6 |
sodium-glucose cotransporter-2 inhibitors |
6 |
soluble receptor for advanced glycation end-products |
6 |
southern chinese women |
6 |
spontaneously hypertensive rats |
6 |
st segment elevation myocardial infarction |
6 |
stability |
6 |
statin |
6 |
steroidogenic |
6 |
stomach |
6 |
stomach cancer |
6 |
structural identification |
6 |
structure-activity relationship |
6 |
suicide |
6 |
superoxide dismutase - metabolism |
6 |
supplementation |
6 |
swine |
6 |
telomere length |
6 |
thiazolidinedione |
6 |
timi grading system |
6 |
timosaponin aiii |
6 |
tnf receptor-associated factor 6 - genetics - metabolism |
6 |
tp receptors |
6 |
transcription factor gata 2 |
6 |
transmission electronic microscopy |
6 |
tumor necrosis factor-α |
6 |
ubiquitination |
6 |
umbilical veins |
6 |
uncaria rhynchophylla |
6 |
undiagnosed diabetes |
6 |
variability |
6 |
volume–outcome |
6 |
volume–quality |
6 |
zebrafish |
6 |
17β-estradiol |
5 |
5-hydroxytryptamine |
5 |
action potentials - drug effects |
5 |
adaptor proteins, signal transducing - antagonists and inhibitors - genetics - physiology |
5 |
adaptor proteins, signal transducing - metabolism |
5 |
adenine - analogs and derivatives - metabolism - pharmacology |
5 |
adenoviridae - genetics |
5 |
adhd |
5 |
adipocyte fatty-acid-binding protein |
5 |
adiponectin - biosynthesis - metabolism |
5 |
adiponectin - blood - genetics - metabolism |
5 |
adiponectin - deficiency - therapeutic use |
5 |
adiponectin and adipokine |
5 |
adipose tissue - drug effects - metabolism |
5 |
adult cardiology |
5 |
adulthood |
5 |
adverse drug event |
5 |
adverse drug reaction |
5 |
aerosol |
5 |
affinity chromatography |
5 |
ageing |
5 |
aging - metabolism |
5 |
agranulocytosis |
5 |
alleles |
5 |
amp-activated protein kinases - metabolism |
5 |
androstadienes - administration & dosage |
5 |
anesthesia |
5 |
anti-inflammatory |
5 |
anticoagulant |
5 |
anticoagulation |
5 |
antineoplastic agents - pharmacology |
5 |
antiplatelets |
5 |
antivirals |
5 |
aorta, thoracic - drug effects - metabolism - physiopathology |
5 |
appl2 |
5 |
association study |
5 |
atenolol - pharmacology |
5 |
avascular necrosis |
5 |
bacteriuria |
5 |
bdmards |
5 |
berberine |
5 |
bioaccumulation |
5 |
biofilm |
5 |
biofilms |
5 |
biomedicine |
5 |
biostatistics |
5 |
blood glucose |
5 |
blood glucose - drug effects |
5 |
blood pressure - drug effects |
5 |
bone density - genetics - physiology |
5 |
booster |
5 |
bronchiectasis - drug therapy |
5 |
caffeine |
5 |
calycosin |
5 |
canagliflozin |
5 |
cancer risk |
5 |
cancer stem cells |
5 |
cancer therapy |
5 |
carcinoma, hepatocellular - metabolism - pathology |
5 |
cardiac dysfunction |
5 |
cardio-renal metabolic syndrome |
5 |
cardiovascular safety of biologics |
5 |
carotid artery diseases - diagnosis |
5 |
carrier proteins - metabolism |
5 |
cell adhesion molecules |
5 |
cell aging - drug effects - physiology |
5 |
cell apoptosis (细胞凋亡) |
5 |